[go: up one dir, main page]

US20060115533A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
US20060115533A1
US20060115533A1 US11/255,359 US25535905A US2006115533A1 US 20060115533 A1 US20060115533 A1 US 20060115533A1 US 25535905 A US25535905 A US 25535905A US 2006115533 A1 US2006115533 A1 US 2006115533A1
Authority
US
United States
Prior art keywords
rapamycin
compositions
compound
composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/255,359
Inventor
Patrice Guitard
Barbara Haeberlin
Rainer Link
Friedrich Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060115533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9514397.0A external-priority patent/GB9514397D0/en
Priority claimed from GBGB9515025.6A external-priority patent/GB9515025D0/en
Application filed by Individual filed Critical Individual
Priority to US11/255,359 priority Critical patent/US20060115533A1/en
Publication of US20060115533A1 publication Critical patent/US20060115533A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • This invention relates to oral pharmaceutical compositions comprising a macrolide, e.g. a rapamycin or an ascomycin, in a solid dispersion.
  • a macrolide e.g. a rapamycin or an ascomycin
  • Rapamycin is an immunosuppressive lactam macrolide produceable, for example by Streptomyces hygroscopicus.
  • the structure of rapamycin is given in Kesseler, H., et al.; 1993; Helv. Chim. Acta; 76: 117.
  • Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability.
  • rapamycin is highly insoluble in aqueous media, e.g. water, making it difficult to formulate stable galenic compositions. Numerous derivatives of rapamycin are known.
  • rapamycins are disclosed in WO 94/02136, the contents of which are incorporated herein by reference.
  • 40-O-substituted rapamycins are described in, e.g., in U.S. Pat. No. 5,258,389 and WO 94/09010 (O-aryl and O-alkyl rapamycins); WO 92/05179 (carboxylic acid esters), U.S. Pat. No. 5,118,677 (amide esters), U.S. Pat. No. 5,118,678 (carbamates), U.S. Pat. No. 5,100,883 (fluorinated esters), U.S. Pat. No.
  • rapamycin derivatives are described in PCT application number EP96/02441, for example 32-deoxorapamycin as described in Example 1, and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin as described in Examples 2 and 3.
  • the contents of PCT application number EP96/02441 are incorporated herein by reference.
  • Rapamycin and its structurally similar analogues and derivatives are termed collectively herein as “rapamycins”.
  • rapamycins On oral administration to humans, solid rapamycins, e.g. rapamycin, may not be absorbed to any significant extent into the bloodstream. Simple mixtures are known for rapamycins, e.g. rapamycin, with conventional pharmaceutical excipients; however, disadvantages encountered with these compositions include unpredictable dissolution rates, irregular bioavailability profiles, and instability. To date there is no conveniently administrable oral solid formulation available for rapamycin or a derivative thereof.
  • this invention provides a pharmaceutical composition in the form of a solid dispersion comprising a rapamycin and a carrier medium.
  • compositions of this invention provide a high bioavailability of drug substance, are convenient to administer, and are stable.
  • rapamycin used in the compositions of this invention may be any rapamycin or derivative thereof, for example as disclosed above or in the above-mentioned patent applications.
  • rapamycin used in the solid dispersion compositions of this invention may be rapamycin or an O-substituted derivative in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by —OR 1 , in which R 1 is hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl and aminoalkyl; e.g.
  • rapamycin derivative may be a 26- or 28-substituted derivative.
  • Preferred rapamycins for use in the solid dispersion compositions of-this invention include rapamycin, 40-O-(2-hydroxy)ethyl rapamycin, 32-deoxorapamycin and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin.
  • a more preferred rapamycin is 40-O-(2-hydroxy)ethyl rapamycin (hereinafter referred to as compound X).
  • Numbering of rapamycin derivatives as used herein refers to the structure disclosed as Formula A at page 4 of published PCT application WO 96/13273, the contents of which are incorporated herein by reference.
  • solid dispersion as used herein is understood to mean a co-precipitate of the rapamycin, e.g. 40-O-(2-hydroxy)ethyl rapamycin or rapamycin, with the carrier medium.
  • the rapamycin is in amorphous or substantially amorphous form and is physically bound to the carrier medium.
  • compositions of this invention may be administered in any convenient form, for example tablet, capsule, granule or powder form, e.g. in a sachet.
  • the rapamycin may be present in the composition in an amount of about 0.01 to about 30-weight-% based on the weight of the composition (% w/w), and preferably in an amount of 1 to 20% w/w based on the total weight of the composition.
  • the carrier medium is present in an amount of up to 99.99% by weight, for example 10 to 95 wt-%, based on the total weight of the composition.
  • the carrier medium comprises a water-soluble polymer, preferably a cellulose derivative such as hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, or polyvinylpyrrrolidone (PVP).
  • HPMC hydroxypropylmethylcellulose
  • PVP polyvinylpyrrrolidone
  • HPMC with a low apparent dynamic viscosity, e.g. below 100 cps as measured at 20° C. for a 2% by weight aqueous solution, e.g below 50 cps, preferably below 20 cps, for example HPMC 3 cps.
  • HPMC is well-known and described, for example, in the Handbook of Pharmaceutical Excipients, Second Edition, pub. Pharmaceutical Society of Great Britain and American Pharmaceutical Association, 1994, p. 229 to 232, the contents of which are incorporated herein by reference.
  • HPMC including HPMC 3 cps, is available commercially under the trade name Pharmacoat 603 from the Shinetsu company.
  • PVP is available, for example, under the name Povidone (Handbook of Pharmaceutical Excipients), and a PVP having an average molecular weight between about 8,000 and about 50,000 Daltons is preferred.
  • the carrier medium comprises hydroxypropylcellulose (HPC) or a derivative thereof.
  • HPC derivatives include those having low dynamic viscosity in aqueous media, e.g. water, e.g below about 400 cps, e.g below 150 cps as measured in a 2% aqueous solution at 25° C.
  • Preferred HPC derivatives have a low degree of substitution, and an average molecular weight below about 200,000 Daltons, e.g. between 50,000 and 150, 000 Daltons.
  • HPC available commercially include Klucel LF, Klucel EF and Klucel JF from the Aqualon company; and Nisso HPC-L available from Nippon Soda Ltd;
  • the carrier medium may further comprise a water-soluble or water-insoluble saccharose or other acceptable carrier or filler such as lactose, or microcrystalline cellulose.
  • the filler if present, is generally in an amount of up to about 30% by weight, e.g. 0.5 to 20 wt-%, preferably, from about 5 to about 15% by weight of the composition.
  • Microcrystalline cellulose is available commercially under the trade name Avicel, for example from FMC Corporation.
  • the carrier medium may further comprise one or more surfactants, for example a non-ionic, ionic, anionic or amphoteric surfactant.
  • surfactants for example a non-ionic, ionic, anionic or amphoteric surfactant.
  • suitable surfactants include
  • the surfactant(s) is generally in an amount of up to about 20%, for example 1 to 15% by weight.
  • One or more disintegrants may be included in the compositions of this invention.
  • disintegrants include Polyplasdone (Handbook of Pharmaceutical Excipients) available commercially from the ISP company; sodium starch glycolate available commercially from the Generichem company; and crosscarmelose sodium available under the trade mark Ac-di-sol from FMC Corporation.
  • One or more lubricants for example magnesium stearate or colloidal silicon dioxide, may further be included in the composition of this invention in an amount of up to about 5 weight %, e.g. 0.5 to 2 wt-%, based on the weight of the composition.
  • flavouring agents may be included in the compositions of this invention.
  • this invention provides a surfactant-free solid dispersion composition comprising a rapamycin as described herein.
  • Antioxidants and/or stabilisers may be included in the compositions of this invention in an amount of up to about 1% by weight, for example between 0.05 and 0.5% by weight.
  • antioxidants include butylated hydroxytoluene, DL- ⁇ -tocopherol, propyl gallate, ascobyl palmitate and fumaric acid.
  • Malonic acid is an appropriate stabiliser.
  • the composition comprises up to 30% by weight, e.g. 1 to 20 wt-%, 40-O-(2-hydroxy)ethyl rapamycin, and up to 95%, e.g. 30 to 90%, HPMC by weight.
  • the weight ratio of the rapamycin to carrier medium in the compositions of this invention is generally no more than 1:3, preferably less than 1:4.
  • this invention provides a process for preparing a solid dispersion composition as described herein.
  • compositions of this invention may be obtained by dissolving or suspending the rapamycin and carrier medium in a solvent or solvent mixture.
  • the solvent may be a single solvent or mixture of solvents, and the order of dissolution and suspension of the rapamycin with the carrier medium in the solvent may be varied.
  • Solvents suitable for use in preparing solid dispersion compositions of this invention may be organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethylacetate; an ether, e.g. diethyl ether, a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane.
  • a convenient solvent mixture is an ethanol/acetone mixture having a weight ratio of ethanol to acetone of between about 1:10 to about 10:1, for example 1:5 to 5:1.
  • the rapamycin and carrier medium are present in a ratio by weight with the solvent of 1:0.1 to 1:20.
  • the solvent may be evaporated and the rapamycin co-precipitated with carrier medium.
  • the resulting residue may be dried, for example under reduced pressure, sieved and milled.
  • the milled dispersion may be combined with other excipients and, for example, compressed as a tablet, or filled into sachets or gelatin capsules.
  • the solid dispersion compositions may be prepared by melting the carrier medium to form a melt, and combining the melt with the rapamycin, e.g. by stirring, optionally in the presence of a solvent or solvent mixture as described herein.
  • the solid dispersions of this invention may be prepared by spray drying techniques as described, for example, in Theory and Practice of Industrial Pharmacy, Lachmann et al., 1986.
  • a suspension as formed above is dispersed through a nozzle into a chamber maintained at, for example, 20 to 80° C.
  • the solvent is evaporated on passing through the nozzle, and finely dispersed particles are collected.
  • compositions of this invention after milling, typically have a mean particle size of less than about 0.5 mm, for example less than about 350 ⁇ m, e.g. about 100 to about 300 ⁇ m.
  • compositions of this invention are useful for the known indications of the rapamycin, e.g. the following conditions:
  • each unit dosage will suitably contain between 1 mg and 100 mg of the drug substance, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg.
  • Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.
  • compositions to be administered depends on several factors, for example the desired duration of treatment and the rate of release of the rapamycin.
  • compositions can be observed in standard clinical tests in, for example, known indications of active agent dosages giving equivalent blood levels of active agent; for example using dosages in the range of 1 mg to 1000 mg, e.g. 5 mg to 100 mg, of active agent per day for a 75 kilogram adult and in standard animal models.
  • dosages in the range of 1 mg to 1000 mg, e.g. 5 mg to 100 mg, of active agent per day for a 75 kilogram adult and in standard animal models for example using dosages in the range of 1 mg to 1000 mg, e.g. 5 mg to 100 mg, of active agent per day for a 75 kilogram adult and in standard animal models.
  • the increased bioavailability of the drug substance provided by the compositions can be observed in standard animal tests and in clinical trials.
  • the dosage form used may be coated, for example using an enteric coating.
  • Suitable coatings may comprise cellulose acetate phthalate; hydroxypropylmethylcellulose phthalate; a polymethyacrylic acid copolymer, e.g. Eudragit L, S; or hydroxypropylmethylcellulose succinate.
  • the rapamycin used in the compositions of this invention may be in crystalline or amorphous form prior to formation of the solid dispersion.
  • An advantage, therefore, of this invention is that the rapamycin need not be crystalline.
  • the rapamycin may be used directly in combination, for example with a solvent, and does not have to be isolated in advance.
  • Another advantage of the invention is that dissolution rates of the solid dispersion are higher than dissolution rates found for a crystalline rapamycin or an amorphous rapamycin in a simple mixture.
  • this invention provides a pharmaceutical composition in the form of a solid dispersion comprising an ascomycin and a carrier medium.
  • Suitable ascomycins for use in the solid dispersion compositions of this invention include ascomycin or a derivative thereof, e.g. 33epi-chloro-33-desoxy-ascomycin.
  • this invention provides a pharmaceutical composition in the form of a solid dispersion comprising 33-epi-chloro-33-desoxy-ascomycin and a carrier medium.
  • compositions of this invention provide a high bioavailability of drug substance, are convenient to administer, and are stable.
  • the ascomycin e.g. compound Y
  • the carrier medium may comprise any of the aforementioned components in amounts by wt-% as described above.
  • Suitable water-soluble polymers, cyclodextrins and other excipients, e.g. surfactants, for use in the 33-epi-chloro-33-desoxy-ascomycin compositions of this invention are as described above.
  • this invention provides a surfactant-containing composition
  • a surfactant-containing composition comprising an ascomycin, e.g. compound Y, in the form of a solid dispersion as described herein.
  • the weight ratio of the ascomycin, e.g. compound Y, to carrier medium is generally no more than 1:3, preferably less than 1:4.
  • the ascomycin e.g. compound Y
  • solid dispersion compositions may be prepared in analogous manner to the processes described above.
  • compositions of compound Y disclosed herein are useful, for example, in the treatment of inflammatory and hyperproliferative skin diseases and of cutaneous manifestations of immunologically-mediated diseases. More specifically, the compositions of this invention are useful as antiinflammatory and as immunosuppressant and antiproliferative agents for use in the prevention and treatment of inflammatory conditions and of conditions requiring immunosuppression, such as
  • each unit dosage will suitably contain between 1 mg and 100 mg of the drug substance, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg.
  • Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.
  • the composition comprises 30% by weight compound Y and 70% by weight HPMC in a dosage of e.g. 10 to 50 mg per day for use in, e.g. psoriasis, atopical dermatitis or contact dermatitis.
  • compositions to be administered depends on several factors, for example the desired duration of treatment and the rate of release of compound Y.
  • compositions containing compound Y can be observed in standard clinical tests in, for example, known indications of active agent dosages giving equivalent blood levels of active agent; for example using dosages in the range of 1 mg to 1000 mg of active agent per day for a 75 kilogram adult and in standard animal models.
  • the increased bioavailability of the drug substance provided by the compositions can be observed in standard animal tests and in clinical trials.
  • FIG. 1 is a graph of mean blood levels of 33-epi-chloro-33-desoxy-ascomycin in rats resulting from administration of Forms E, F and G as described in Examples 7, 8 and 9.
  • FIG. 2 is a graph of blood levels of 33-epi-chloro-33-desoxy-ascomycin in rats resulting from the administration of Forms E and F, as described in Examples 7 and 8, when the Forms are with food.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 9.1 HPMC 3 cps 81.8 Lactose 200 mesh 9.1
  • the composition (Form A) is prepared by dissolving the rapamycin and carrier medium in an ethanol/acetone mixture. Absolute ethanol is used in a 1:1 ratio by weight with the acetone. The solvents are then evaporated, and the resulting dry residue milled to a fine powder with mean particle size ⁇ 0.5 mm.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 16.7 HPMC 3 cps 66.7 Poloxamer 188 (from BASF) 16.7
  • the composition (Form B) is prepared in analogous manner to that in Example 1.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 16.7 HPMC 3 cps 66.7 TPGS* 16.7 *tocopherol polyethylene glycol succinate
  • the composition (Form C) is prepared in analogous manner to that in Example 1.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 10 HPMC 3 cps 80 Solulan C24 (from Amerchol) 10
  • the composition (Form D) is prepared in analogous manner to that in Example 1.
  • compositions Forms A to D may be formed into tablets, filled into capsules, or powdered and packaged in sachets.
  • 0.5 ml aqueous dispersions of the Compound X compositions were administered by gastric intubation during a short inhalation anaesthesia with a 1 ml syringe, attached to a polyethylene tube. Six animals were used for each composition Forms A, B, C and D.
  • the blood samples were analysed using reversed phase HPLC.
  • Table 1 shows the pharmacokinetic data collected after administration of Compound X to rats.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 20 HPMC 3 cps 80
  • the composition (Form E) is prepared by dissolving compound Y and carrier medium in an ethanol/acetone mixture. The solvents are then evaporated, and the resulting dry residue milled.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 20 HPMC 3 cps 70 Poloxamer 188 10
  • the composition (Form F) is prepared in analogous manner to that in Example 5.
  • a solid dispersion composition is prepared containing the following ingredients (in parts by weight): Compound X 20 HPMC 3 cps 75 Sodium laurylsulfate 5
  • the composition (Form G) is prepared in analogous manner to that in Example 7.
  • compositions Forms E to G may be formed into tablets, filled into capsules, or powdered and packaged in sachets.
  • 0.5 ml aqueous dispersions of the drug compositions were administered by gastric intubation during a short inhalation anaesthesia with a 1 ml syringe, attached to a polyethylene tube.
  • Six animals were used for each composition Forms E, F, and G.
  • the blood samples were analysed using reversed phase HPLC.
  • FIGS. 1 and 2 The results are plotted in FIGS. 1 and 2 , in which ng/ml (vertical axis) is plotted against time in hours (horizontal axis).
  • FIG. 1 shows that Form F resulted in blood levels substantially higher than blood levels observed after administration of Form E or Form G.
  • FIG. 2 shows that Form F resulted in high blood levels when administered with food.
  • Compound Y is in amorphous form in the compositions E, F and G on formation and after 6 months storage as determined by X-ray diffraction.
  • Forms E, F and G are tested for respective dissolution rates. On stirring in a solution of 0.2 wt % sodium dodecylsulfate in water at 37° C., it is found that over 80% available compound Y is released and dissolved from each milled composition containing 10 mg compound Y after 30 minutes. 92% available compound Y is released from Form E. This compares with approximately 5% release after 30 minutes from an equivalent amount of crystalline compound Y.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

Description

    BACKGROUND AND SUMMARY
  • This invention relates to oral pharmaceutical compositions comprising a macrolide, e.g. a rapamycin or an ascomycin, in a solid dispersion.
  • Rapamycin is an immunosuppressive lactam macrolide produceable, for example by Streptomyces hygroscopicus. The structure of rapamycin is given in Kesseler, H., et al.; 1993; Helv. Chim. Acta; 76: 117. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability. Moreover, rapamycin is highly insoluble in aqueous media, e.g. water, making it difficult to formulate stable galenic compositions. Numerous derivatives of rapamycin are known. Certain 16-O-substituted rapamycins are disclosed in WO 94/02136, the contents of which are incorporated herein by reference. 40-O-substituted rapamycins are described in, e.g., in U.S. Pat. No. 5,258,389 and WO 94/09010 (O-aryl and O-alkyl rapamycins); WO 92/05179 (carboxylic acid esters), U.S. Pat. No. 5,118,677 (amide esters), U.S. Pat. No. 5,118,678 (carbamates), U.S. Pat. No. 5,100,883 (fluorinated esters), U.S. Pat. No. 5,151,413 (acetals), U.S. Pat. No. 5,120,842 (silyl ethers), WO 93/11130 (methylene rapamycin and derivatives), WO 94/02136 (methoxy derivatives), WO 94/02385 and WO 95/14023 (alkenyl derivatives) all of which are incorporated herein by reference. 32-O-dihydro or substituted rapamycin are described, e.g., in U.S. Pat. No. 5,256,790, incorporated herein by reference.
  • Further rapamycin derivatives are described in PCT application number EP96/02441, for example 32-deoxorapamycin as described in Example 1, and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin as described in Examples 2 and 3. The contents of PCT application number EP96/02441 are incorporated herein by reference.
  • Rapamycin and its structurally similar analogues and derivatives are termed collectively herein as “rapamycins”.
  • On oral administration to humans, solid rapamycins, e.g. rapamycin, may not be absorbed to any significant extent into the bloodstream. Simple mixtures are known for rapamycins, e.g. rapamycin, with conventional pharmaceutical excipients; however, disadvantages encountered with these compositions include unpredictable dissolution rates, irregular bioavailability profiles, and instability. To date there is no conveniently administrable oral solid formulation available for rapamycin or a derivative thereof.
  • Accordingly, in one aspect, this invention provides a pharmaceutical composition in the form of a solid dispersion comprising a rapamycin and a carrier medium.
  • The compositions of this invention provide a high bioavailability of drug substance, are convenient to administer, and are stable.
  • The rapamycin used in the compositions of this invention may be any rapamycin or derivative thereof, for example as disclosed above or in the above-mentioned patent applications.
  • Thus the rapamycin used in the solid dispersion compositions of this invention may be rapamycin or an O-substituted derivative in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by —OR1, in which R1 is hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl and aminoalkyl; e.g. as described in WO94/09010, for example 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-(2-acetaminoethyl)-rapamycin. The rapamycin derivative may be a 26- or 28-substituted derivative.
  • Preferred rapamycins for use in the solid dispersion compositions of-this invention include rapamycin, 40-O-(2-hydroxy)ethyl rapamycin, 32-deoxorapamycin and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin. A more preferred rapamycin is 40-O-(2-hydroxy)ethyl rapamycin (hereinafter referred to as compound X).
  • Numbering of rapamycin derivatives as used herein refers to the structure disclosed as Formula A at page 4 of published PCT application WO 96/13273, the contents of which are incorporated herein by reference.
  • The term solid dispersion as used herein is understood to mean a co-precipitate of the rapamycin, e.g. 40-O-(2-hydroxy)ethyl rapamycin or rapamycin, with the carrier medium. In the solid dispersion, the rapamycin is in amorphous or substantially amorphous form and is physically bound to the carrier medium.
  • Compositions of this invention may be administered in any convenient form, for example tablet, capsule, granule or powder form, e.g. in a sachet.
  • The rapamycin may be present in the composition in an amount of about 0.01 to about 30-weight-% based on the weight of the composition (% w/w), and preferably in an amount of 1 to 20% w/w based on the total weight of the composition.
  • The carrier medium is present in an amount of up to 99.99% by weight, for example 10 to 95 wt-%, based on the total weight of the composition.
  • In one-embodiment the carrier medium comprises a water-soluble polymer, preferably a cellulose derivative such as hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose phthalate, or polyvinylpyrrrolidone (PVP). Good results may be obtained using HPMC with a low apparent dynamic viscosity, e.g. below 100 cps as measured at 20° C. for a 2% by weight aqueous solution, e.g below 50 cps, preferably below 20 cps, for example HPMC 3 cps. HPMC is well-known and described, for example, in the Handbook of Pharmaceutical Excipients, Second Edition, pub. Pharmaceutical Society of Great Britain and American Pharmaceutical Association, 1994, p. 229 to 232, the contents of which are incorporated herein by reference. HPMC, including HPMC 3 cps, is available commercially under the trade name Pharmacoat 603 from the Shinetsu company.
  • PVP is available, for example, under the name Povidone (Handbook of Pharmaceutical Excipients), and a PVP having an average molecular weight between about 8,000 and about 50,000 Daltons is preferred.
  • In another embodiment the carrier medium comprises hydroxypropylcellulose (HPC) or a derivative thereof. Examples of HPC derivatives include those having low dynamic viscosity in aqueous media, e.g. water, e.g below about 400 cps, e.g below 150 cps as measured in a 2% aqueous solution at 25° C. Preferred HPC derivatives have a low degree of substitution, and an average molecular weight below about 200,000 Daltons, e.g. between 50,000 and 150, 000 Daltons. Examples of HPC available commercially include Klucel LF, Klucel EF and Klucel JF from the Aqualon company; and Nisso HPC-L available from Nippon Soda Ltd;
      • a polyethylene glycol (PEG). Examples include PEGs having an average molecular weight between 1000 and 9000 Daltons, e.g. between about 1800 and 7000, for example PEG 2000, PEG 4000 or PEG 6000 (Handbook of Pharmaceutical Excipients);
      • a saturated polyglycolised glyceride, available for example under the trade mark Gelucir, e.g. Gelucir 44/14, 53/10, 50/13, 42/12, or 35/10 from the Gattefosse company; or
      • a cyclodextrin, for example a P-cyclodextrin or an x-cyclodextrin. Examples of suitable β-cyclodextrins include methyl-β-cyclodextrin; dimethyl-β-cyclodextrin; hydroxypropyl-β-cyclodextrin; glycosyl-β-cyclodextrin; maltosyl-β-cyclodextrin; sulfo-β-cyclodextrin; sulfo-alkylethers of β-cyclodextrin, e.g. sulfo-C1-4-alkyl ethers. Examples of α-cyclodextrins include glucosyl-α-cyclodextrin and maltosyl-α-cyclodextrin.
  • The carrier medium may further comprise a water-soluble or water-insoluble saccharose or other acceptable carrier or filler such as lactose, or microcrystalline cellulose. The filler, if present, is generally in an amount of up to about 30% by weight, e.g. 0.5 to 20 wt-%, preferably, from about 5 to about 15% by weight of the composition. Microcrystalline cellulose is available commercially under the trade name Avicel, for example from FMC Corporation.
  • The carrier medium may further comprise one or more surfactants, for example a non-ionic, ionic, anionic or amphoteric surfactant. Examples of suitable surfactants include
      • polyoxyethylene-polyoxypropylene co-polymers and block co-polymers known, for example, under the trade names Pluronic or Poloxamer, e.g. as described in Fiedler, H. P. “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete”, Editio Cantor, D-7960 Aulendorf, 3rd revised and expanded edition (1989), the contents of which are hereby incorporated by reference. A preferred polyoxyethylene-polyoxypropylene block polymer is Poloxamer 188 available from the BASF company;
      • ethoxylated cholesterins known, for example, under the trade name Solulan, for example Solulan C24 commercially available from the Amerchol company;
      • vitamin derivatives, e.g. vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS) available from the Eastman company;
      • sodium dodecylsulfate or sodium laurylsulfate;
      • a bile acid or salt thereof, for example cholic acid, glycolic acid or a salt, e.g. sodium cholate; or
      • lecithin.
  • If present in the compositions of this invention, the surfactant(s) is generally in an amount of up to about 20%, for example 1 to 15% by weight.
  • One or more disintegrants may be included in the compositions of this invention. Examples of disintegrants include Polyplasdone (Handbook of Pharmaceutical Excipients) available commercially from the ISP company; sodium starch glycolate available commercially from the Generichem company; and crosscarmelose sodium available under the trade mark Ac-di-sol from FMC Corporation. One or more lubricants, for example magnesium stearate or colloidal silicon dioxide, may further be included in the composition of this invention in an amount of up to about 5 weight %, e.g. 0.5 to 2 wt-%, based on the weight of the composition.
  • It may be advantageous to include one or more flavouring agents in the compositions of this invention.
  • The present applicants have obtained good results using surfactant-free rapamycin compositions. In another aspect, therefore, this invention provides a surfactant-free solid dispersion composition comprising a rapamycin as described herein.
  • Antioxidants and/or stabilisers may be included in the compositions of this invention in an amount of up to about 1% by weight, for example between 0.05 and 0.5% by weight. Examples of antioxidants include butylated hydroxytoluene, DL-α-tocopherol, propyl gallate, ascobyl palmitate and fumaric acid. Malonic acid is an appropriate stabiliser.
  • In one embodiment of this invention, the composition comprises up to 30% by weight, e.g. 1 to 20 wt-%, 40-O-(2-hydroxy)ethyl rapamycin, and up to 95%, e.g. 30 to 90%, HPMC by weight.
  • The weight ratio of the rapamycin to carrier medium in the compositions of this invention is generally no more than 1:3, preferably less than 1:4.
  • In another aspect, this invention provides a process for preparing a solid dispersion composition as described herein.
  • In one embodiment the compositions of this invention may be obtained by dissolving or suspending the rapamycin and carrier medium in a solvent or solvent mixture. The solvent may be a single solvent or mixture of solvents, and the order of dissolution and suspension of the rapamycin with the carrier medium in the solvent may be varied. Solvents suitable for use in preparing solid dispersion compositions of this invention may be organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethylacetate; an ether, e.g. diethyl ether, a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane. A convenient solvent mixture is an ethanol/acetone mixture having a weight ratio of ethanol to acetone of between about 1:10 to about 10:1, for example 1:5 to 5:1.
  • Typically the rapamycin and carrier medium are present in a ratio by weight with the solvent of 1:0.1 to 1:20. The solvent may be evaporated and the rapamycin co-precipitated with carrier medium. The resulting residue may be dried, for example under reduced pressure, sieved and milled. The milled dispersion may be combined with other excipients and, for example, compressed as a tablet, or filled into sachets or gelatin capsules.
  • In another embodiment, the solid dispersion compositions may be prepared by melting the carrier medium to form a melt, and combining the melt with the rapamycin, e.g. by stirring, optionally in the presence of a solvent or solvent mixture as described herein.
  • Alternatively the solid dispersions of this invention may be prepared by spray drying techniques as described, for example, in Theory and Practice of Industrial Pharmacy, Lachmann et al., 1986. A suspension as formed above is dispersed through a nozzle into a chamber maintained at, for example, 20 to 80° C. The solvent is evaporated on passing through the nozzle, and finely dispersed particles are collected.
  • The compositions of this invention, after milling, typically have a mean particle size of less than about 0.5 mm, for example less than about 350 μm, e.g. about 100 to about 300 μm.
  • The oral compositions of this invention are useful for the known indications of the rapamycin, e.g. the following conditions:
      • a) Treatment and prevention of organ or tissue allo- or xeno-transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. They are also indicated for the prevention of graft-versus-host disease, such as following bone marrow transplantation.
      • b) Treatment and prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the invention may be employed include, autoimmune hematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.
      • c) Treatment and prevention of asthma
      • d) Treatment of multi-drug resistance (MDR). MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp. The compositions are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.
      • e) Treatment of proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like.
      • f) Treatment of fungal infections.
      • g) Treatment and prevention of inflammation, especially in potentiating the action of steroids.
      • h) Treatment and prevention of infection, especially infection by pathogens having Mip or Mip-like factors.
      • i) Treatment of overdoses of FK-506 and other macrophilin binding immunosuppressants.
  • Where the pharmaceutical composition of this invention is in unit dosage form, e.g. as a tablet, capsule, granules or powder, each unit dosage will suitably contain between 1 mg and 100 mg of the drug substance, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg. Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.
  • The exact amount of the compositions to be administered depends on several factors, for example the desired duration of treatment and the rate of release of the rapamycin.
  • The utility of the pharmaceutical compositions can be observed in standard clinical tests in, for example, known indications of active agent dosages giving equivalent blood levels of active agent; for example using dosages in the range of 1 mg to 1000 mg, e.g. 5 mg to 100 mg, of active agent per day for a 75 kilogram adult and in standard animal models. The increased bioavailability of the drug substance provided by the compositions can be observed in standard animal tests and in clinical trials.
  • The dosage form used, e.g. a tablet, may be coated, for example using an enteric coating. Suitable coatings may comprise cellulose acetate phthalate; hydroxypropylmethylcellulose phthalate; a polymethyacrylic acid copolymer, e.g. Eudragit L, S; or hydroxypropylmethylcellulose succinate.
  • The rapamycin used in the compositions of this invention, e.g. 40-0-(2-hydroxy)ethyl rapamycin or rapamycin, may be in crystalline or amorphous form prior to formation of the solid dispersion. An advantage, therefore, of this invention is that the rapamycin need not be crystalline. Thus the rapamycin may be used directly in combination, for example with a solvent, and does not have to be isolated in advance. Another advantage of the invention is that dissolution rates of the solid dispersion are higher than dissolution rates found for a crystalline rapamycin or an amorphous rapamycin in a simple mixture.
  • In another aspect, this invention provides a pharmaceutical composition in the form of a solid dispersion comprising an ascomycin and a carrier medium.
  • Examples of suitable ascomycins for use in the solid dispersion compositions of this invention include ascomycin or a derivative thereof, e.g. 33epi-chloro-33-desoxy-ascomycin.
  • To date there is no conveniently administrable oral solid formulation available for 33-epi-chloro-33-desoxy-ascomycin. In another aspect, therefore, this invention provides a pharmaceutical composition in the form of a solid dispersion comprising 33-epi-chloro-33-desoxy-ascomycin and a carrier medium.
  • The compound 33-epi-chloro-33-desoxy-ascomycin is described in published European application EP 427 680 under Example 66a.
  • 33-epi-chloro-33-desoxy-ascomycin will be referred to hereinafter as Compound Y.
  • The ascomycin, e.g. compound Y, compositions of this invention provide a high bioavailability of drug substance, are convenient to administer, and are stable.
  • The ascomycin, e.g. compound Y, may be present in the composition in an amount of about 0.01 to about 30% w/w, and preferably in an amount of 1 to 20% w/w.
  • The carrier medium may comprise any of the aforementioned components in amounts by wt-% as described above. Suitable water-soluble polymers, cyclodextrins and other excipients, e.g. surfactants, for use in the 33-epi-chloro-33-desoxy-ascomycin compositions of this invention are as described above.
  • In a preferred aspect, this invention provides a surfactant-containing composition comprising an ascomycin, e.g. compound Y, in the form of a solid dispersion as described herein.
  • The weight ratio of the ascomycin, e.g. compound Y, to carrier medium is generally no more than 1:3, preferably less than 1:4.
  • The ascomycin, e.g. compound Y, solid dispersion compositions may be prepared in analogous manner to the processes described above.
  • The oral compositions of compound Y disclosed herein are useful, for example, in the treatment of inflammatory and hyperproliferative skin diseases and of cutaneous manifestations of immunologically-mediated diseases. More specifically, the compositions of this invention are useful as antiinflammatory and as immunosuppressant and antiproliferative agents for use in the prevention and treatment of inflammatory conditions and of conditions requiring immunosuppression, such as
      • a) the prevention and treatment of
        • rejection of organ or tissue transplantation, e.g. of heart, kidney, liver, bone marrow and skin, graft-versus-host disease, such as following bone marrow grafts,
        • autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, Myasthenia gravis, diabetes type I and uveitis,
        • cutaneous manifestations of immunologically-mediated illnesses;
      • b) the treatment of inflammatory and hyperproliferative skin diseases, such as psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus and acne; and
      • c) Alopecia areata.
  • Where the pharmaceutical composition of this invention is in unit dosage form, e.g. as a tablet, capsule or powder, each unit dosage will suitably contain between 1 mg and 100 mg of the drug substance, more preferably between 10 and 50 mg; for example 15, 20, 25, or 50 mg. Such unit dosage forms are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.
  • In one embodiment of this invention, the composition comprises 30% by weight compound Y and 70% by weight HPMC in a dosage of e.g. 10 to 50 mg per day for use in, e.g. psoriasis, atopical dermatitis or contact dermatitis.
  • The exact amount of the compositions to be administered depends on several factors, for example the desired duration of treatment and the rate of release of compound Y.
  • The utility of the pharmaceutical compositions containing compound Y can be observed in standard clinical tests in, for example, known indications of active agent dosages giving equivalent blood levels of active agent; for example using dosages in the range of 1 mg to 1000 mg of active agent per day for a 75 kilogram adult and in standard animal models. The increased bioavailability of the drug substance provided by the compositions can be observed in standard animal tests and in clinical trials.
  • Following is a description by way of example only of solid dispersion compositions of this invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph of mean blood levels of 33-epi-chloro-33-desoxy-ascomycin in rats resulting from administration of Forms E, F and G as described in Examples 7, 8 and 9.
  • FIG. 2 is a graph of blood levels of 33-epi-chloro-33-desoxy-ascomycin in rats resulting from the administration of Forms E and F, as described in Examples 7 and 8, when the Forms are with food.
    • EXAMPLE 1
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 9.1
    HPMC 3 cps 81.8
    Lactose 200 mesh 9.1

    The composition (Form A) is prepared by dissolving the rapamycin and carrier medium in an ethanol/acetone mixture. Absolute ethanol is used in a 1:1 ratio by weight with the acetone. The solvents are then evaporated, and the resulting dry residue milled to a fine powder with mean particle size <0.5 mm.
    • EXAMPLE 2
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 16.7
    HPMC 3 cps 66.7
    Poloxamer 188 (from BASF) 16.7

    The composition (Form B) is prepared in analogous manner to that in Example 1.
    • EXAMPLE 3
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 16.7
    HPMC 3 cps 66.7
    TPGS* 16.7

    *tocopherol polyethylene glycol succinate

    The composition (Form C) is prepared in analogous manner to that in Example 1.
    • EXAMPLE 4
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 10
    HPMC 3 cps 80
    Solulan C24 (from Amerchol) 10

    The composition (Form D) is prepared in analogous manner to that in Example 1.
  • The above compositions Forms A to D may be formed into tablets, filled into capsules, or powdered and packaged in sachets.
    • EXAMPLE 5 Pharmacokinetics after Administration of 40-O-(2-hydroxy) Ethyl Rapamycin to Rats
  • a) Drug Administration
  • 0.5 ml aqueous dispersions of the Compound X compositions (corresponding to 4.0 mg active ingredient/rat) were administered by gastric intubation during a short inhalation anaesthesia with a 1 ml syringe, attached to a polyethylene tube. Six animals were used for each composition Forms A, B, C and D.
  • b) Blood Sampling
  • The animals received a permanent cannula into a vena jugularis one day prior to this experiment. 0.5 ml venous blood (vena jugularis) was collected from each rat and stored in 2.5 ml EDTA tubes. The blood samples of 2 animals (1 and 2, 3 and 4, 5 and 6) were pooled and stored at −80° C. until drug analysis. Samples were taken before administration and 10 minutes (m), 30 m, 60 m, 120 m, 300 m, 480 m and 1440 m after drug administration.
  • c) Bioanalytics
  • The blood samples were analysed using reversed phase HPLC.
  • Table 1 shows the pharmacokinetic data collected after administration of Compound X to rats.
    TABLE 1
    Summary Profiles
    (averages of 2-3 pools)
    blood concentration (ng/ml)
    time (h) Form A Form B Form C Form D
    0 7 7 7 7
    0.17 118 117 85 68
    0.5 422 131 125 74
    1 375 129 96 66
    2 277 82 89 54
    5 573 92 58 39
    8 496 66 45 34
    24 93 30 34 30
    Cmax (ng/ml) 573 135 131 81
    Tmax (hr) 5.00 0.50 0.50 0.50
    AUC 0-8 h 3502 720 565 376
    [(ng/ml).h]
    AUC 0-24 h 8213 1487 1192 886
    [(ng/ml).h]

    Form A resulted in blood levels higher than those after administration of surfactant-containing compositions.
    • EXAMPLE 6 Dog Study
  • Following the above promising results, a relative bioavailability study was performed in fasted beagle dogs using a dose of 1 mg/kg body weight. Hard gelatin capsules each containing 10 mg compound X were administered to 8 dogs in a 4-way latin square design; the dogs were fed 6 hours post administration of the capsules, and blood levels of compound X were determined over 48 hours. Similar blood concentration profiles of compound X were observed for all the dogs, with a terminal halflife of compound X in blood between 10 and 40 hours. Median peak levels of 140 ng/ml and median AUC levels of 048 hr ca. 1600 ng.h/ml were observed.
    • EXAMPLE 7
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 20
    HPMC 3 cps 80

    The composition (Form E) is prepared by dissolving compound Y and carrier medium in an ethanol/acetone mixture. The solvents are then evaporated, and the resulting dry residue milled.
    • EXAMPLE 8
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 20
    HPMC 3 cps 70
    Poloxamer 188 10

    The composition (Form F) is prepared in analogous manner to that in Example 5.
    • EXAMPLE 9
  • A solid dispersion composition is prepared containing the following ingredients (in parts by weight):
    Compound X 20
    HPMC 3 cps 75
    Sodium laurylsulfate  5

    The composition (Form G) is prepared in analogous manner to that in Example 7.
  • The above compositions Forms E to G may be formed into tablets, filled into capsules, or powdered and packaged in sachets.
    • EXAMPLE 10 Pharmacokinetics after Administration of 33-epi-chloro-33-desoxy-ascomycin to Rats
  • a) Drug Administration
  • 0.5 ml aqueous dispersions of the drug compositions (corresponding to 4.0 mg active ingredient/rat) were administered by gastric intubation during a short inhalation anaesthesia with a 1 ml syringe, attached to a polyethylene tube. Six animals were used for each composition Forms E, F, and G.
  • b) Blood Sampling
  • The animals received a permanent cannula into a vena jugularis one day prior to this experiment. 0.5 ml venous blood (vena jugularis) was collected from each rat and stored in 2.5 ml EDTA tubes. The blood samples of 2 animals (1 and 2, 3 and 4, 5 and 6) were pooled and stored at −80° C. until drug analysis. Samples were taken before administration and 10 minutes (m), 30 m, 60 m, 120 m, 300 m, 480 m and 1440 m after drug administration.
  • c) Bioanalytics
  • The blood samples were analysed using reversed phase HPLC.
  • The results are plotted in FIGS. 1 and 2, in which ng/ml (vertical axis) is plotted against time in hours (horizontal axis).
  • FIG. 1 shows that Form F resulted in blood levels substantially higher than blood levels observed after administration of Form E or Form G.
  • FIG. 2 shows that Form F resulted in high blood levels when administered with food.
  • Compound Y is in amorphous form in the compositions E, F and G on formation and after 6 months storage as determined by X-ray diffraction.
  • Forms E, F and G are tested for respective dissolution rates. On stirring in a solution of 0.2 wt % sodium dodecylsulfate in water at 37° C., it is found that over 80% available compound Y is released and dissolved from each milled composition containing 10 mg compound Y after 30 minutes. 92% available compound Y is released from Form E. This compares with approximately 5% release after 30 minutes from an equivalent amount of crystalline compound Y.

Claims (2)

1-10. (canceled)
11. A method of forming a pharmaceutical composition comprising 33-epi-chloro-33-desoxy-ascomycin and a carrier medium wherein the method comprises:
(a) suspending the 33-epi-chloro-33-desoxy-ascomycin in a solvent to form a suspension,
(b) combining one or more carrier components with the solvent, and
(c) spray drying the suspension to form the pharmaceutical composition.
US11/255,359 1995-07-14 2005-10-21 Pharmaceutical compositions Abandoned US20060115533A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/255,359 US20060115533A1 (en) 1995-07-14 2005-10-21 Pharmaceutical compositions

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9514397.0 1995-07-14
GBGB9514397.0A GB9514397D0 (en) 1995-07-14 1995-07-14 Organic compounds
GB9515025.6 1995-07-21
GBGB9515025.6A GB9515025D0 (en) 1995-07-21 1995-07-21 Organic compounds
US08/981,952 US6004973A (en) 1995-07-14 1996-07-12 Pharmaceutical compositions comprising rafamycin coprecipitates
PCT/EP1996/003066 WO1997003654A2 (en) 1995-07-14 1996-07-12 Pharmaceutical compositions
US9374899A 1999-08-13 1999-08-13
US72573300A 2000-11-29 2000-11-29
US10/194,826 US6599535B2 (en) 1995-07-14 2002-07-12 Pharmaceutical compositions
US10/454,017 US6956043B2 (en) 1995-07-14 2003-06-04 Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions
US11/255,359 US20060115533A1 (en) 1995-07-14 2005-10-21 Pharmaceutical compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/454,017 Division US6956043B2 (en) 1995-07-14 2003-06-04 Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions

Publications (1)

Publication Number Publication Date
US20060115533A1 true US20060115533A1 (en) 2006-06-01

Family

ID=26307397

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/981,952 Expired - Lifetime US6004973A (en) 1995-07-14 1996-07-12 Pharmaceutical compositions comprising rafamycin coprecipitates
US09/374,899 Expired - Lifetime US6197781B1 (en) 1995-07-14 1999-08-13 Pharmaceutical compositions
US10/194,826 Expired - Fee Related US6599535B2 (en) 1995-07-14 2002-07-12 Pharmaceutical compositions
US10/454,017 Expired - Fee Related US6956043B2 (en) 1995-07-14 2003-06-04 Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions
US11/255,359 Abandoned US20060115533A1 (en) 1995-07-14 2005-10-21 Pharmaceutical compositions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US08/981,952 Expired - Lifetime US6004973A (en) 1995-07-14 1996-07-12 Pharmaceutical compositions comprising rafamycin coprecipitates
US09/374,899 Expired - Lifetime US6197781B1 (en) 1995-07-14 1999-08-13 Pharmaceutical compositions
US10/194,826 Expired - Fee Related US6599535B2 (en) 1995-07-14 2002-07-12 Pharmaceutical compositions
US10/454,017 Expired - Fee Related US6956043B2 (en) 1995-07-14 2003-06-04 Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions

Country Status (30)

Country Link
US (5) US6004973A (en)
EP (2) EP1281400B1 (en)
JP (4) JPH11509223A (en)
KR (1) KR100352943B1 (en)
CN (1) CN1080120C (en)
AT (2) ATE258429T1 (en)
AU (1) AU706174B2 (en)
BE (1) BE1009856A5 (en)
BR (1) BR9609537A (en)
CA (2) CA2225960C (en)
CL (1) CL2003002715A1 (en)
CY (2) CY2603B2 (en)
CZ (1) CZ291305B6 (en)
DE (2) DE69635499T2 (en)
DK (2) DK1281400T3 (en)
ES (2) ES2215195T3 (en)
FR (1) FR2736550B1 (en)
HU (1) HU226774B1 (en)
IL (2) IL144684A (en)
IT (1) IT1284871B1 (en)
NO (2) NO314924B1 (en)
NZ (1) NZ313633A (en)
PL (1) PL191933B1 (en)
PT (1) PT839028E (en)
RU (1) RU2159107C2 (en)
SI (2) SI0839028T1 (en)
SK (2) SK283571B6 (en)
TR (1) TR199800045T1 (en)
UY (1) UY25896A1 (en)
WO (1) WO1997003654A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US11110067B2 (en) 2008-11-11 2021-09-07 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US11191750B2 (en) 2013-03-13 2021-12-07 The Board Of Regents Of The University Of Texas System Use of mTOR inhibitors for treatment of familial adenomatous polyposis

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
NZ507211A (en) * 1998-03-26 2003-07-25 Fujisawa Pharmaceutical Co Sustained release preparations
JP3718341B2 (en) 1998-05-12 2005-11-24 信越化学工業株式会社 Low substituted hydroxypropylcellulose and process for producing the same
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
AU2003200370B2 (en) * 1998-12-07 2005-10-27 Novartis Ag Stabilization of macrolides
EP1980263A1 (en) 1999-05-10 2008-10-15 Novartis AG Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
EP2269654A3 (en) 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6680069B1 (en) 1999-11-09 2004-01-20 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose and process for manufacturing the same
ATE329579T1 (en) 1999-11-12 2006-07-15 Abbott Lab SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
RU2264405C2 (en) * 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-hydroxy)ethylrapamycin in crystalline nonsolvated form, pharmaceutical composition comprising such macrolide as active substance and method for its preparing
JP3552160B2 (en) 2000-01-14 2004-08-11 信越化学工業株式会社 Method for forming low-substituted hydroxypropylcellulose particles
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
WO2002089796A2 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
ES2485841T3 (en) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compounds containing phosphorus and uses thereof
ATE395044T1 (en) 2002-02-01 2008-05-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
MXPA04007428A (en) * 2002-02-01 2004-10-11 Pfizer Prod Inc Immediate release dosage forms containing solid drug dispersions.
JP3956114B2 (en) * 2002-06-28 2007-08-08 インターナショナル・ビジネス・マシーンズ・コーポレーション Display control method, program using the same, information processing apparatus, and optical character reader
US20060035879A1 (en) * 2002-11-15 2006-02-16 Prescott Margaret F Organic Compounds
AR043504A1 (en) * 2003-03-17 2005-08-03 Novartis Ag PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
BRPI0412329A (en) * 2003-07-09 2006-09-05 Chong Kun Dang Pharm Corp tacrolimus solid dispersion and method of processing the same
MXPA06001417A (en) * 2003-08-04 2006-05-15 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
MXPA06007829A (en) * 2004-01-08 2006-09-01 Wyeth Corp Directly compressible pharmaceutical composition for the oral admimistration of cci-779.
US7655442B2 (en) 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
JP2007534693A (en) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド DPI formulation containing sulfoalkyl ether cyclodextrin
DE602005024012D1 (en) 2004-08-27 2010-11-18 Cordis Corp SOLVENT-FREE AMORPHES RAPAMYCIN
JP2008514706A (en) * 2004-09-29 2008-05-08 コーディス・コーポレイション Pharmaceutical dosage forms of stable amorphous rapamycin-like compounds
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
KR100678824B1 (en) * 2005-02-04 2007-02-05 한미약품 주식회사 Amorphous tacrolimus solid dispersion with increased solubility and pharmaceutical composition comprising the same
US20060182771A1 (en) 2005-02-09 2006-08-17 Dor Philippe J Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008532953A (en) * 2005-03-08 2008-08-21 ライフサイクル ファーマ エー／エス Pharmaceutical composition comprising sirolimus and / or related substances
WO2006102359A2 (en) * 2005-03-23 2006-09-28 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20060240108A1 (en) * 2005-04-26 2006-10-26 Bernard Bobby L Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
DE102005026755A1 (en) * 2005-06-09 2006-12-14 Basf Ag Production of solid solutions of sparingly soluble active ingredients by short-term overheating and rapid drying
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2662082A1 (en) 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
EP1938800A1 (en) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2118656B1 (en) 2006-12-29 2012-08-29 Abbott Laboratories Improved assay for immunosuppressant drugs
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
CN102036572A (en) 2008-03-20 2011-04-27 维尔恩公司 Emulsions containing PEG derivatives of tocopherol
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
FR2943539B1 (en) 2009-03-31 2011-07-22 Ethypharm Sa PHARMACEUTICAL COMPOSITION COMPRISING A IMMUNOSUPPRESSIVE MACROLIDE OF THE LIMUS FAMILY.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (en) * 2009-06-08 2016-07-01 亞培公司 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
JP5779591B2 (en) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド ABT-263 capsule
EP2563164B1 (en) 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
RU2585489C2 (en) 2010-04-27 2016-05-27 Рош Гликарт Аг COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR
IT1400977B1 (en) * 2010-07-01 2013-07-05 Euticals Spa NEW COMPLEXES OF PHARMACEUTICAL, SOLID, SOLUBLE IN WATER AND THEIR WATER SOLUTIONS FOR ORAL, OPHTHALMIC, TOPICAL OR PARENTERAL USE, CONTAINING A MACROLIDE AND SOME CYCLODEXTRINES.
KR20180059560A (en) 2010-10-29 2018-06-04 애브비 인코포레이티드 Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
PT2643322T (en) 2010-11-23 2017-11-13 Abbvie Inc SALTS AND CRYSTALLINE FORMS OF AN APOPTOSE INDUCING AGENT
PH12013501006A1 (en) 2010-11-23 2022-03-30 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
WO2012092421A2 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US20120303115A1 (en) * 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
KR101151890B1 (en) * 2011-08-11 2012-05-31 동아제약주식회사 Method of preparing a stabilized and solubilized formulation of sirolimus derivatives
JP6368242B2 (en) 2011-10-06 2018-08-01 ノバルティス アーゲー Pharmaceutical composition comprising 40-O- (2-hydroxy) ethyl-rapamycin
EP2594260A1 (en) * 2011-11-18 2013-05-22 LEK Pharmaceuticals d.d. Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
KR200477251Y1 (en) * 2011-12-30 2015-05-22 엘에스산전 주식회사 Main contact position indicating mechanism for molded case circuit breaker
CN103585122B (en) * 2012-08-17 2017-12-05 山东新时代药业有限公司 A kind of tablet containing everolimus and preparation method thereof
CA2926747A1 (en) 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201503912A (en) * 2013-03-19 2015-02-01 Novartis Ag Pharmaceutical compositions comprising everolimus
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2015073644A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
CN103610646B (en) * 2013-12-05 2015-07-15 江苏奥赛康药业股份有限公司 Composition containing everolimus and preparation method thereof, and pharmaceutical preparation containing composition
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
CN104721158B (en) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 A kind of everolimus tablet of stabilization
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3104891A1 (en) 2014-02-11 2016-12-21 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
KR102487608B1 (en) 2014-04-07 2023-01-12 노파르티스 아게 Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3131546B1 (en) 2014-04-16 2022-02-16 Rapamycin Holdings, Inc. Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
CN107109419B (en) 2014-07-21 2020-12-22 诺华股份有限公司 Cancer treatment using the CD33 chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR102804360B1 (en) 2014-09-17 2025-05-12 노파르티스 아게 Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA40910A (en) 2014-11-07 2017-09-12 Civitas Therapeutics Inc RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition including rapamycin or derivative thereof, and production method therefor
JP6793651B2 (en) * 2015-08-28 2020-12-02 日本化薬株式会社 Pharmaceutical composition containing rapamycin or a derivative thereof
EP3345601A4 (en) * 2015-09-03 2019-05-15 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition containing rapamycin or derivative thereof
WO2017204215A1 (en) 2016-05-27 2017-11-30 日本化薬株式会社 Pharmaceutical composition containing rapamycin or derivative thereof
CN116769050A (en) 2016-07-20 2023-09-19 犹他大学研究基金会 CD229 CAR T cells and methods of use thereof
JP6857663B2 (en) * 2016-10-04 2021-04-14 日本化薬株式会社 Method for Producing Solid Dispersion Containing Rapamycin Derivative
MX2019003886A (en) 2016-10-07 2019-08-05 Novartis Ag Chimeric antigen receptors for the treatment of cancer.
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
CN107080738A (en) * 2017-04-26 2017-08-22 四川制药制剂有限公司 The preparation method of acetylspiramycin tablet
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US11541152B2 (en) 2018-11-14 2023-01-03 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
CN114025800A (en) * 2019-06-26 2022-02-08 株式会社理光 Pharmaceutical composition
US20220401421A1 (en) * 2019-12-19 2022-12-22 Triviumvet Dac Veterinary formulations comprising rapamycin and methods of using the same for treating animal disease
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3929992A (en) * 1972-09-29 1975-12-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4421738A (en) * 1979-07-31 1983-12-20 Eisai Co., Ltd. Sugar-coated tablet containing fat-soluble pharmaceutical material
US4610875A (en) * 1982-04-19 1986-09-09 Elan Corporation, P.L.C. Medicaments with a high degree of solubility and method for their production
US4650666A (en) * 1983-11-30 1987-03-17 Dainippon Pharmaceutical Co., Ltd. Pullulan and sugar coated pharmaceutical composition
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4916138A (en) * 1986-04-02 1990-04-10 Fujisawa Pharmaceutical Co., Ltd. Solid dispersion composition of FR-900506 substance
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5384130A (en) * 1990-04-18 1995-01-24 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5387589A (en) * 1991-07-25 1995-02-07 University Of Louisville Research Foundation, Inc. Method of treating ocular inflammation
US5456923A (en) * 1991-04-16 1995-10-10 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5514686A (en) * 1991-04-26 1996-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5530006A (en) * 1992-03-30 1996-06-25 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5559121A (en) * 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5665772A (en) * 1992-10-09 1997-09-09 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5691334A (en) * 1993-12-23 1997-11-25 Pharmacia & Upjohn S.P.A. Pyrrolydenemethyl-derivatives and process for their preparation
US5725883A (en) * 1995-01-09 1998-03-10 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5766523A (en) * 1995-06-07 1998-06-16 Conoco Inc. Blow spinning die and process for spinning carbon fibers from solvated pitches
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US5780062A (en) * 1994-11-09 1998-07-14 The Ohio State University Research Foundation Small particle formation
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
US5932243A (en) * 1993-05-27 1999-08-03 Novartis Ag Galenical formulations
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6004973A (en) * 1995-07-14 1999-12-21 Novartis Ag Pharmaceutical compositions comprising rafamycin coprecipitates
US6262127B1 (en) * 1993-08-27 2001-07-17 Novartis Ag Polymeric matrices and their uses in pharmaceutical compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
IE58836B1 (en) * 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
US4659336A (en) 1986-03-28 1987-04-21 Texaco Inc. Motor fuel composition
DE3823702A1 (en) 1988-07-13 1990-01-25 Bayer Ag PROCESS FOR PREPARING POLYESTERS CONTAINING ACRYLOYL GROUPS AND THEIR USE AS PAINT BINDERS
GB2222683B (en) 1988-08-17 1992-04-15 Hydramotion Ltd Device for moisture measurement of particulate material
PT93772A (en) * 1989-04-17 1991-01-08 Searle & Co PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF NEOPLASMS, CONTAINING AN ANTI-NEOPLASTIC AGENT, FOR EXAMPLE DOXORUBICIN AND A PROTEIN AGENT TO REDUCE THE SIDE EFFECTS, FOR EXAMPLE CARBETIMER
ATE126803T1 (en) * 1989-11-09 1995-09-15 Sandoz Ag TRICYCLIC COMPOUNDS CONTAINING HETEROATOMS.
JPH03240726A (en) * 1990-02-15 1991-10-28 Fujisawa Pharmaceut Co Ltd Chemotherapeutic effect enhancer
AU7908791A (en) 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
EP0542860B1 (en) 1990-08-10 1998-05-20 AnorMED Inc Immunosuppressive compositions
IL101353A0 (en) 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DK0525960T3 (en) 1991-06-18 1996-04-15 American Home Prod Use of rapamycin for the treatment of T-cell leukemia / lymphoma
AU670937B2 (en) 1992-04-28 1996-08-08 Wyeth Method of treating hyperproliferative vascular disease
US5315246A (en) 1992-08-19 1994-05-24 Eastman Kodak Company Rotating source for generating a magnetic field for use with a currency detector
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
DE4322826A1 (en) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
DE4329503A1 (en) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmaceutical preparations for the targeted treatment of Crohn's disease and ulcerative colitis
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
JPH10513200A (en) 1995-02-06 1998-12-15 ナノシステムズ エルエルシー Formulation of compounds that are fine particle dispersions in digestible oils or fatty acids
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
JP3934705B2 (en) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 Cyclodextrin composition
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
JP3226545B2 (en) 1995-06-09 2001-11-05 ノバルティス・アクチエンゲゼルシャフト Rapamycin derivative
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19635999A1 (en) 1996-09-05 1998-03-12 Dystar Textilfarben Gmbh & Co Dye mixtures of fiber-reactive azo dyes and their use for dyeing fiber material containing hydroxyl and / or carbonamide groups

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3929992A (en) * 1972-09-29 1975-12-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4421738A (en) * 1979-07-31 1983-12-20 Eisai Co., Ltd. Sugar-coated tablet containing fat-soluble pharmaceutical material
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4610875A (en) * 1982-04-19 1986-09-09 Elan Corporation, P.L.C. Medicaments with a high degree of solubility and method for their production
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4650666A (en) * 1983-11-30 1987-03-17 Dainippon Pharmaceutical Co., Ltd. Pullulan and sugar coated pharmaceutical composition
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
US4753801B1 (en) * 1985-10-25 1992-07-14 Lilly Co Eli
US4916138A (en) * 1986-04-02 1990-04-10 Fujisawa Pharmaceutical Co., Ltd. Solid dispersion composition of FR-900506 substance
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
US5384130A (en) * 1990-04-18 1995-01-24 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5456923A (en) * 1991-04-16 1995-10-10 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5514686A (en) * 1991-04-26 1996-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
US5387589A (en) * 1991-07-25 1995-02-07 University Of Louisville Research Foundation, Inc. Method of treating ocular inflammation
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
US5530006A (en) * 1992-03-30 1996-06-25 American Home Products Corporation Rapamycin formulation for IV injection
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5665772A (en) * 1992-10-09 1997-09-09 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5932243A (en) * 1993-05-27 1999-08-03 Novartis Ag Galenical formulations
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US6262127B1 (en) * 1993-08-27 2001-07-17 Novartis Ag Polymeric matrices and their uses in pharmaceutical compositions
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5559121A (en) * 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5691334A (en) * 1993-12-23 1997-11-25 Pharmacia & Upjohn S.P.A. Pyrrolydenemethyl-derivatives and process for their preparation
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US5780062A (en) * 1994-11-09 1998-07-14 The Ohio State University Research Foundation Small particle formation
US5725883A (en) * 1995-01-09 1998-03-10 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5759576A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
US5766523A (en) * 1995-06-07 1998-06-16 Conoco Inc. Blow spinning die and process for spinning carbon fibers from solvated pitches
US6004973A (en) * 1995-07-14 1999-12-21 Novartis Ag Pharmaceutical compositions comprising rafamycin coprecipitates
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11110067B2 (en) 2008-11-11 2021-09-07 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US11191750B2 (en) 2013-03-13 2021-12-07 The Board Of Regents Of The University Of Texas System Use of mTOR inhibitors for treatment of familial adenomatous polyposis
US12383538B2 (en) 2013-03-13 2025-08-12 The Board Of Regents Of The University Of Texas System Use of mTOR inhibitors for prevention of intestinal polyp growth and cancer
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US11077061B2 (en) 2013-12-31 2021-08-03 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use

Also Published As

Publication number Publication date
ATE258429T1 (en) 2004-02-15
WO1997003654A3 (en) 1997-03-20
SI1281400T1 (en) 2006-06-30
DE69631422D1 (en) 2004-03-04
IL144684A0 (en) 2002-06-30
CZ9198A3 (en) 1998-04-15
DE69635499T2 (en) 2006-08-03
IL122905A0 (en) 1998-08-16
EP0839028B1 (en) 2004-01-28
CY2571B1 (en) 2008-07-02
IL144684A (en) 2007-03-08
CA2426956A1 (en) 1997-02-06
NO980081D0 (en) 1998-01-08
EP1281400A2 (en) 2003-02-05
SK283571B6 (en) 2003-09-11
RU2159107C2 (en) 2000-11-20
FR2736550B1 (en) 1998-07-24
IL122905A (en) 2003-07-06
CY2603B2 (en) 2010-04-28
NZ313633A (en) 1999-05-28
AU706174B2 (en) 1999-06-10
JP2012082217A (en) 2012-04-26
UY25896A1 (en) 2001-10-25
HU226774B1 (en) 2009-09-28
SK283572B6 (en) 2003-09-11
DK1281400T3 (en) 2006-04-03
ITRM960501A1 (en) 1998-01-12
SI0839028T1 (en) 2004-06-30
US6599535B2 (en) 2003-07-29
WO1997003654A2 (en) 1997-02-06
US20030211160A1 (en) 2003-11-13
PL324502A1 (en) 1998-05-25
CA2225960C (en) 2004-05-11
NO314924B1 (en) 2003-06-16
CN1080120C (en) 2002-03-06
DE69635499D1 (en) 2005-12-29
SK4498A3 (en) 1998-05-06
ES2250566T3 (en) 2006-04-16
NO317702B1 (en) 2004-12-06
AU6615296A (en) 1997-02-18
BR9609537A (en) 1999-02-23
CA2225960A1 (en) 1997-02-06
PT839028E (en) 2004-05-31
HK1016081A1 (en) 1999-10-29
FR2736550A1 (en) 1997-01-17
JP5522901B2 (en) 2014-06-18
EP0839028A2 (en) 1998-05-06
JPH11509223A (en) 1999-08-17
US20030008835A1 (en) 2003-01-09
KR100352943B1 (en) 2003-03-06
NO980081L (en) 1998-01-08
HUP9900391A2 (en) 1999-06-28
CZ291305B6 (en) 2003-01-15
JP2004002457A (en) 2004-01-08
ITRM960501A0 (en) 1996-07-12
CA2426956C (en) 2008-09-02
IT1284871B1 (en) 1998-05-22
BE1009856A5 (en) 1997-10-07
HUP9900391A3 (en) 2001-08-28
US6004973A (en) 1999-12-21
TR199800045T1 (en) 1998-05-21
NO20025089D0 (en) 2002-10-23
PL191933B1 (en) 2006-07-31
JP2008150395A (en) 2008-07-03
ES2215195T3 (en) 2004-10-01
NO20025089L (en) 1998-01-18
KR19990028942A (en) 1999-04-15
CN1195289A (en) 1998-10-07
US6956043B2 (en) 2005-10-18
DE69631422T2 (en) 2004-11-04
EP1281400A3 (en) 2003-11-05
DK0839028T3 (en) 2004-06-01
US6197781B1 (en) 2001-03-06
CL2003002715A1 (en) 2005-05-20
EP1281400B1 (en) 2005-11-23
ATE310519T1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US6599535B2 (en) Pharmaceutical compositions
EP2193788B1 (en) Pharmaceutical compositions comprising colloidal silicon dioxide
HK1141239B (en) Pharmaceutical compositions comprising colloidal silicon dioxide
HK1067036B (en) Pharmaceutical compositions comprising colloidal silicon dioxide

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION